Onkológia 2/2024

Current options in the treatment of HER2 low metastatic breast cancer

The expansion of the spectrum of human epidermal growth factor receptor 2 (HER2)-status to HER2-low, defined as HER2 expression of 1+ by immunohistochemistry (IHC) or 2+ by IHC without gene amplification, has made a major impact in the treatment of breast cancer. The HER2-low expression has emerged as a targetable biomarker, and anti-HER2 antibody-drug conjugate trastuzumab deruxtecan has shown significant survival benefit in pretreated metastatic HER2-low breast cancer (BC). With these recent data, the treatment algorithm for HR+ and TNBC needs to be reconsidered, as approximately half of these BCs are HER2-low. Although there are different therapeutic agents for HR+ and HR- HER2-low BCs, there is no consensus regarding the sequencing of these agents in this cohor of patients.

Keywords: HER2 lov breast cancer, triple negative breast cancer, trastuzumab deruxtecan, sacituzumab govitecan, PARP inhibitors, alpelisib, everolimus, brain metastases